IsolicoflavonolCAS# 94805-83-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 94805-83-1 | SDF | Download SDF |
PubChem ID | 5318585 | Appearance | Yellow powder |
Formula | C20H18O6 | M.Wt | 354.36 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3,5,7-trihydroxy-2-[4-hydroxy-3-(3-methylbut-2-enyl)phenyl]chromen-4-one | ||
SMILES | CC(=CCC1=C(C=CC(=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)C | ||
Standard InChIKey | PGCKDCPTJAQQSQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H18O6/c1-10(2)3-4-11-7-12(5-6-14(11)22)20-19(25)18(24)17-15(23)8-13(21)9-16(17)26-20/h3,5-9,21-23,25H,4H2,1-2H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Isolicoflavonol is a potential cancer chemopreventive agent. |
Isolicoflavonol Dilution Calculator
Isolicoflavonol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.822 mL | 14.1099 mL | 28.2199 mL | 56.4398 mL | 70.5497 mL |
5 mM | 0.5644 mL | 2.822 mL | 5.644 mL | 11.288 mL | 14.1099 mL |
10 mM | 0.2822 mL | 1.411 mL | 2.822 mL | 5.644 mL | 7.055 mL |
50 mM | 0.0564 mL | 0.2822 mL | 0.5644 mL | 1.1288 mL | 1.411 mL |
100 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.5644 mL | 0.7055 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Glycycoumarin
Catalog No.:BCN7685
CAS No.:94805-82-0
- 20(R)-Notoginsenoside R2
Catalog No.:BCN3864
CAS No.:948046-15-9
- Bruceine J
Catalog No.:BCN8001
CAS No.:948038-38-8
- Bruceantinol A
Catalog No.:BCN8003
CAS No.:948038-36-6
- 3-pyr-Cytisine
Catalog No.:BCC6118
CAS No.:948027-43-8
- ML365
Catalog No.:BCC8063
CAS No.:947914-18-3
- HBTU
Catalog No.:BCC2814
CAS No.:94790-37-1
- TCFH
Catalog No.:BCC2824
CAS No.:94790-35-9
- WWL 70
Catalog No.:BCC4011
CAS No.:947669-91-2
- 7,3'-Dihydroxy-5'-methoxyisoflavone
Catalog No.:BCN3349
CAS No.:947611-61-2
- Salmeterol xinafoate
Catalog No.:BCC1920
CAS No.:94749-08-3
- Fmoc-Aib-OH
Catalog No.:BCC3149
CAS No.:94744-50-0
- Tie2 kinase inhibitor
Catalog No.:BCC2561
CAS No.:948557-43-5
- Acuminatanol
Catalog No.:BCN6866
CAS No.:948884-38-6
- 2beta-(Isobutyryloxy)florilenalin
Catalog No.:BCN7976
CAS No.:94898-78-9
- Z-Gly-NH2
Catalog No.:BCC2769
CAS No.:949-90-6
- H-Phe(4-NO2)-OH
Catalog No.:BCC3293
CAS No.:949-99-5
- Sodium formononetin-3'-sulfonate
Catalog No.:BCC1960
CAS No.:949021-68-5
- 6-(4-Hydroxy-3-methylphenyl)-2-methylhept-2-en-4-one
Catalog No.:BCN7514
CAS No.:949081-05-4
- 8-Hydroxy-ar-turmerone
Catalog No.:BCN7513
CAS No.:949081-09-8
- 6-Methoxynaringenin
Catalog No.:BCN4500
CAS No.:94942-49-1
- Gypenoside XLIX
Catalog No.:BCN1207
CAS No.:94987-08-3
- Quercetin-3-o-rutinose
Catalog No.:BCN3404
CAS No.:949926-49-2
- Thianaphthene
Catalog No.:BCC9178
CAS No.:95-15-8
Preliminary identification of the absorbed bioactive components and metabolites in rat plasma after oral administration of Shaoyao-Gancao decoction by ultra-performance liquid chromatography with electrospray ionization tandem mass spectrometry.[Pubmed:25422552]
Pharmacogn Mag. 2014 Oct;10(40):497-502.
BACKGROUND: Shaoyao-Gancao decoction (SGD), a traditional Chinese medicine formula, has been used for the treatment of abdominal pain and dysmenorrhea disease in Asia over long period of time. Its effectiveness has been confirmed in clinic, but its active constituents remain unclear. MATERIALS AND METHODS: In this paper, a rapid, sensitive and reliable ultra-performance liquid chromatography-electrospray ionization/quadrupole-time-of-flight high-definition mass spectrometry (UPLC-ESI-Q-TOF-MS) in positive and negative ion mode were established to characterize the active constituents of SGD in vitro. The analysis was performed on a Waters UPLCTM HSS T3 (2.1 x 100 mm, 1.8 microm) using gradient elution system. Automated MetaboLynxTM technique was employed to screen for the potentially bioactive components in rat plasma after oral administration of SGD. MS/MS fragmentation behavior was proposed for aiding the structural identification of the components. RESULTS: Based on the developed method of fingerprint analysis, an injection run of the plasma sample was finished in 15.0 min. A total of 12 compounds including 9 prototype components such as gallicacid, albiflorin, liquiritin, pallidiflorin, liquiritigenin, isoLiquiritigenin, formononetin, Isolicoflavonol, licoricone, C9H10O3 and 2 metabolites such as liquiritigenin-4'-O-glucuronide, formononetin glucuronide were identified or tentatively characterized. Of note, 3 ingredients were identified from Radix Paeoniae Alba, and 9 were from Radix Glycyrrhizae. CONCLUSION: The compounds found in dosed plasma could be the effective substances of SGT for treating dysmenorrheal, and may provide important experimental data for further pharmacological and clinical research of SGD. Furthermore, this work has demonstrated that the feasibility of the UPLC-ESI-Q-TOF-MS for rapid and reliable characterization of identification and structural elucidation of the chemical constituents and their metabolites from herbal medicines.
Natural inhibitors of carcinogenesis.[Pubmed:15326546]
Planta Med. 2004 Aug;70(8):691-705.
Previous collaborative work by our group has led to the discovery of several plant isolates and derivatives with activities in in vivo models of cancer chemoprevention, including deguelin, resveratrol, bruceantin, brassinin, 4'-bromoflavone, and oxomate. Using a panel of in vitro bioassays to monitor chromatographic fractionation, a diverse group of plant secondary metabolites has been identified as potential cancer chemopreventive agents from mainly edible plants. Nearly 50 new compounds have been isolated as bioactive principles in one or more in vitro bioassays in work performed over the last five years. Included among these new active compounds are alkaloids, flavonoids, stilbenoids, and withanolides, as well as a novel stilbenolignan and the first representatives of the norwithanolides, which have a 27-carbon atom skeleton. In addition, over 100 active compounds of previously known structure have been obtained. Based on this large pool of potential cancer chemopreventive compounds, structure-activity relationships are discussed in terms of the quinone reductase induction ability of flavonoids and withanolides and the cyclooxygenase-1 and -2 inhibitory activities of flavanones, flavones and stilbenoids. Several of the bioactive compounds were found to be active when evaluated in a mouse mammary organ culture assay, when used as a secondary discriminator in our work. The compounds (2 S)-abyssinone II, (2 S)-2',4'-dihydroxy-2"-(1-hydroxy-1-methylethyl)dihydrofuro[2,3- h]-flavanone, 3'-[gamma-hydroxymethyl-( E)-gamma-methylallyl]-2,4,2',4'-tetrahydroxychalcone 11'- O-coumarate, Isolicoflavonol, isoliquiritigenin, and ixocarpalactone A are regarded as promising leads as potential cancer chemopreventive agents.